Home
EOLS
EOLS News

Latest Evolus Inc. (EOLS) News on March 29, 2025

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Business Wire

4 days ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain

Simply Wall St.

6 days ago

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 days ago

Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

Motley Fool

18 days ago

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

Thomson Reuters StreetEvents

24 days ago

Q4 2024 Evolus Inc Earnings Call

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

GuruFocus.com

24 days ago

Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

MT Newswires

24 days ago

Evolus Q4 Net Loss Narrows, Revenue Rises; Issues Guidance

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Zacks

24 days ago

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Business Wire

24 days ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

a month ago

Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Business Wire

a month ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Business Wire

a month ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Business Wire

a month ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Zacks

a month ago

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

a month ago

Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Business Wire

a month ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing

Simply Wall St.

2 months ago

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Zacks

2 months ago

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Investor's Business Daily

2 months ago

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

MT Newswires

2 months ago

Evolus Reports Q4 Preliminary Net Revenue; Shares Rise Pre-Bell

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Business Wire

2 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

Simply Wall St.

3 months ago

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Zacks

4 months ago

Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Zacks

4 months ago

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.

5 months ago

Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Evolus Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

5 months ago

Evolus Third Quarter 2024 Earnings: Misses Expectations

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

GuruFocus.com

5 months ago

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Zacks

5 months ago

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus Reports Third Quarter 2024 Results

Business Wire

5 months ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Business Wire

5 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

MT Newswires

5 months ago

Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Business Wire

5 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Zacks

5 months ago

Insulet (PODD) Earnings Expected to Grow: Should You Buy?

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Zacks

5 months ago

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Business Wire

5 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Business Wire

5 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Simply Wall St.

6 months ago

Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

GuruFocus.com

6 months ago

Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Business Wire

7 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Insider Monkey

8 months ago

Evolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 months ago

Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Investor's Business Daily

8 months ago

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Business Wire

8 months ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Business Wire

8 months ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Business Wire

8 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Business Wire

8 months ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Pharmaceutical Technology

8 months ago

Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues

Evolus to Report Second Quarter Financial Results on July 31, 2024

Business Wire

8 months ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Business Wire

9 months ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

MT Newswires

9 months ago

Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Business Wire

9 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Simply Wall St.

9 months ago

Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Business Wire

10 months ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

10 months ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

GlobeNewswire

10 months ago

ThreeD Capital Inc. Announces Unaudited May 31, 2024 Net Asset Value Per Share - $0.72

Camber Energy Announces Passing of Director Lawrence Fisher

ACCESSWIRE

10 months ago

Camber Energy Announces Passing of Director Lawrence Fisher

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

Newsfile

10 months ago

Ciscom Corp. to Hold Annual and Special Meeting of the Shareholders on August 20, 2024

GlobeNewswire

10 months ago

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

10 months ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

CNW Group

10 months ago

CORUS PROVIDES UPDATE ON PROGRAMMING AND TRADEMARK OUTPUT ARRANGEMENTS

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

CNW Group

10 months ago

Media Advisory - Prime Minister's itinerary for Saturday, June 8, 2024

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 06/07/2024

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space

WWD

10 months ago

The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Zacks

10 months ago

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Business Wire

10 months ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

GuruFocus.com

10 months ago

Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)

Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)

GuruFocus.com

10 months ago

Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

Business Wire

10 months ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

Business Wire

a year ago

Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year

Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q1 2024 Evolus Inc Earnings Call

GuruFocus.com

a year ago

Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth

GuruFocus.com

a year ago

Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth

Evolus Reports First Quarter 2024 Results and Provides Business Update

Business Wire

a year ago

Evolus Reports First Quarter 2024 Results and Provides Business Update

The 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%

Simply Wall St.

a year ago

The 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%

Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?

Zacks

a year ago

Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?

Evolus to Report First Quarter Financial Results on May 7, 2024

Business Wire

a year ago

Evolus to Report First Quarter Financial Results on May 7, 2024

11 Best Low Price Pharma Stocks To Invest In

Insider Monkey

a year ago

11 Best Low Price Pharma Stocks To Invest In

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

Business Wire

a year ago

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company

Simply Wall St.

a year ago

Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

a year ago

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

10 Stocks George Soros and Insiders Are Crazy About

Insider Monkey

a year ago

10 Stocks George Soros and Insiders Are Crazy About

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?

Zacks

a year ago

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Business Wire

a year ago

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report

Simply Wall St.

a year ago

Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report

Evolus Full Year 2023 Earnings: In Line With Expectations

Simply Wall St.

a year ago

Evolus Full Year 2023 Earnings: In Line With Expectations

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Share on Social Networks: